test

Harriet Kluger MD

Associate Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program

Clinical Interests

Melanoma; renal cell carcinoma; breast cancer Clinical trials using immune and biologic therapies


Board Certifications

Hematology (Internal Medicine), Board Eligible
2002
Medical Oncology, Board Certified

Patient Care Locations

harriet_klugerfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Melanoma, skinPhase I/II study to assess the safety and activity of enhanced TCR transduced autologous T cells against cancer-testis antigens in metastatic melanoma
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Melanoma, skinA Phase 1, Open label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma.
Colon, Lung, and RectumA PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
Lung and Melanoma, skinA Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases

More Clinical Trials...

Edit Profile